Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.68 |
| ▸ | CDK2 | P24941 | 8/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.68 |
| ▸ | CDK9 | P50750 | 4/20 | 0.68 |
| ▸ | CDK1 | P06493 | 3/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.68 |
| ▸ | CDK7 | P50613 | 2/20 | 0.68 |
| ▸ | CDK4 | P11802 | 2/20 | 0.68 |
| ▸ | CCND1 | P24385 | 2/20 | 0.68 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.68 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.68 |
| ▸ | CCNH | P51946 | 1/20 | 0.68 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.68 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.68 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.68 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400367 | 0.91 | CCNA2 (0.67) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL4480905 | 0.81 | CDK2 (0.69) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL30337943 | 0.81 | CCNA2 (1.00) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL30439092 | 0.81 | CCNA2 (1.00) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL20408787 | 0.81 | CCNA2 (1.00) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL30097427 | 0.81 | CCNA2 (1.00) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL7757514 | 0.79 | CDK2 (0.80) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL5725244 | 0.75 | CCNA2 (0.59) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL5725679 | 0.75 | CCNA2 (0.76) | CCNA2CDK2CDK5CDK5R1CDK9 | |
| SCHEMBL5725673 | 0.74 | CCNA2 (0.75) | CCNA2CDK2CDK5CDK5R1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| CN-1158269-C | 4-aminothiazole derivs, their preparation and their use as inhibitors of cyclin-dependent kinases | ������ҩ������˾ | 2004-07-21 | — | — | CN | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| CN-1276789-A | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin dependent kinases | AGOURON PHARMA (US) | 2000-12-13 | — | — | CN | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | CCNA2 24/4885CDK2 1/4885CDK5 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.